As a new type of foreign trade service provider driven by both technology commercialization and cross-border trading, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials of wild yam extract diosgenin sourced from multiple well-known original manufacturers. Possessing R&D capabilities, HiSiaddi has partnered with manufacturers on technology transformation and conducted multiple rounds of on-site inspections of wild yam extract diosgenin manufacturers, developing objective and in-depth understanding of different brands. We regularly analyze various manufacturers of wild yam extract diosgenin for clients to help them source matching products. Below is a brand selection delivery case. Contact HiSiaddi customer service for additional brand and model comparative analysis support.
Purchaser: BioBalance Healthcare Pty Ltd, Sydney, Australia A leading mid-to-high-end Australian brand specializing in menopausal conditioning and plant sterol raw material R&D, with products sold across national premium organic supermarket chains, private gynecology clinics and high-end wellness hospitals in Australia. The brand enforces five mandatory entry thresholds for raw materials: Australian TGA pharmaceutical regulatory standards, United States Pharmacopeia (USP), FSMA import control, EU EC396 standard for 226 pesticide residues and cGMP production specifications, rejecting raw materials sourced from artificially cultivated yams and non-standard industrial-grade saponins.
Core product lines include premium menopausal softgels and composite plant tablets, with diosgenin as the core functional raw material in formulations. Mandatory indicators specify wild Qinba Dioscorea zingiberensis feedstock, diosgenin purity of 98.0%±0.3%, split into two customized grades: ultra-fine powder exclusive for softgels and general powder for tablets, with a planned stable annual procurement volume of 21 tons and an 8-month timeline for new product delivery and launch.
The Australian enterprise boasts over a decade of end-formulation expertise and previously imported pharmaceutical-grade diosgenin long-term from Spain and India. Driven by rising overseas raw material prices and extended shipping cycles, it launched China-based sourcing in 2025. New to the domestic plant extract industry, the client lacked full awareness of mainstream domestic diosgenin manufacturers, product models, process pros and cons, certification qualifications and dosage form compatibility. At industry expos and online channels, it sequentially contacted five leading domestic manufacturers: Shaanxi Hongda Bio, Chenggu Zhenhua Bio, Changsha Shanghe Bio, Xi’an Jiayuan Bio and Zhejiang Natural Bio. While all five manufacturers maintained standardized business communication without deliberate competitor defamation, sales teams prioritized promoting their own products under performance KPIs, avoiding objective disclosure of peer product strengths and applicable scenarios and only sending samples of their own brands.
The client received a total of 13 different diosgenin sample models from five manufacturers, sending batches to authoritative Australian third-party laboratories for testing while conducting small and pilot trials in its own GMP formulation workshop. Multiple issues emerged including drastically fluctuating purity levels, powder physical properties incompatible with filling lines, formulation discoloration triggered by raw material impurities and brand compliance qualifications failing Australian TGA entry standards. Cumulative losses from sample testing, auxiliary material waste and production line debugging equated to AUD 35,000, delaying the new product launch plan by 92 days. Unable to independently conduct horizontal comparison of pros and cons across five brands to accurately select raw material models matching its own formulation and production conditions, the client fully entrusted HiSiaddi Foreign Trade via recommendation from the Australian Natural Raw Materials Chamber of Commerce to conduct full-dimensional decomposition and evaluation of the five leading brands as a neutral third party, screening 2 premium mid-to-high-end manufacturers and 3 finalized product models aligned with the client’s formulation and production conditions, coordinating sample re-verification and mass production delivery.
HiSiaddi assembled a dedicated research team consisting of plant extract raw material engineers, Australian regulatory consultants and powder testing specialists, conducting on-site factory visits across Shaanxi, Hunan and Zhejiang, retrieving COA reports, production line certifications and raw material traceability documents from each brand and sorting objective strengths, weaknesses and mainstream product models of the five leading manufacturers combined with measured sample test data, eliminating information bias from one-sided manufacturer marketing.
Located in the Qinba Mountain raw material heartland of Hanzhong, Shaanxi, the enterprise owns fixed wild Dioscorea zingiberensis harvesting cooperatives with outstanding source raw material control capacity, holding full export certifications including GMP, ISO22000, KOSHER and HALAL, supplying premium dietary pharmaceutical enterprises across Europe and America year-round specializing in wild-source high-purity saponins. Three mainstream product models:
1. HD-DIO98A: 98.0%±0.3% pharmaceutical grade raw powder, standard 100-mesh general grade for tablet production, manufactured via enzymatic hydrolysis + recrystallization process with low impurity content and stable cost performance;
2. HD-DIO98B: 98.0% ultra-fine 200-mesh powder processed via low-temperature jet milling, customized exclusively for softgel filling with excellent powder flowability;
3. HD-DIO95: 95% purity cosmetic-grade saponin for external skincare products, not required for the client’s current procurement. Brand strengths: 100% wild Qinba Dioscorea zingiberensis raw materials with zero cultivated yam adulteration, internal pesticide residue standards stricter than EU EC396, industry-leading batch purity stability. Existing weaknesses: Small-batch customized modification sampling lead time of 7–10 days, mid-to-high unit price among the five manufacturers, spot inventory dominated by 98-series pharmaceutical grade with limited low-purity stock.
Founded over 30 years ago with supporting self-owned API synthesis workshops, the enterprise leverages large-scale centralized procurement advantages in the Hanzhong production zone with annual pharmaceutical-grade diosgenin output exceeding 100 tons, serving as a fixed raw material supplier for multiple domestic listed pharmaceutical companies with compliance systems aligned with both Chinese Pharmacopoeia and USP dual standards. Mainstream models:
1. ZH-98PH: Pharmacopoeia-grade 98% saponin, general standard powder with abundant large-batch spot inventory;
2. ZH-95CO: 95% cosmetic-specific raw material. Brand strengths: Controllable costs via large-scale mass production, ten-thousand-ton warehouse spot reserves and stable delivery cycles for large orders, strict internal control of solvent residues. Existing weaknesses: Primary focus on standard particle size powder for bulk shipments; customized 200-mesh ultra-fine powder requires separate production line activation, limited expertise in small-batch dosage-form-specific modification, wild raw material proportion of approximately 75% with the remainder supplemented by standardized cultivated yellow ginger feedstock, resulting in slightly lower maximum finished purity compared to Hongda.
Partnered with Hunan Pharmaceutical Research Institute for technical cooperation, specializing in high-purity plant monomers with complete SMB simulated moving bed chromatographic purification production lines, excelling in ultra-high-purity customized saponins above 98.5% for export primarily as high-end European and American pharmaceutical intermediates. Mainstream model: SH-DIO985 ultra-high-purity grade (98.5%±0.2%), SH-DIO98 general pharmaceutical powder. Brand strengths: Industry-leading purification technology with extremely low miscellaneous peaks on HPLC chromatograms and top-tier impurity control across the sector. Existing weaknesses: Raw materials sourced externally from the Qinba production zone without independent control of source harvesting leading to occasional minor batch fluctuations, highest product pricing among the five manufacturers with elevated minimum order thresholds, unsuitable for the client’s regular mass production fixed demand.
Specializing in niche customized extracts with flexible production lines enabling on-demand adjustment of powder particle size and modification processes, focused on small and medium-batch foreign trade orders with complete food-grade and health product-grade product lines. Mainstream models: JY98-F food-grade 98% saponin, JY90 general feed-grade saponin. Brand strengths: Low minimum order thresholds with expedited small-batch sample delivery and flexible modification processes. Existing weaknesses: No self-owned wild raw material bases with externally sourced raw materials mixed with cultivated yam leading to large fluctuations in active ingredient content per batch, incomplete full set of TGA and USP pharmaceutical-grade certifications failing to fully meet Australian high-end dietary access specifications.
Investing a fixed 8% of annual revenue in product R&D, specializing in raw material compatibility improvement with supporting auxiliary material pre-mixing laboratories, serving as a core supplier for East China health product factories. Mainstream models: ZT98-P tablet-specific saponin, ZT98-S general raw material powder. Brand strengths: Comprehensive downstream formulation supporting services with capacity to assist clients in simple auxiliary material testing. Existing weaknesses: Fully externally sourced raw materials with unstable wild yam supply chains, insufficient stability for continuous large-batch supply, internal pesticide residue control only meeting national standards and failing EU 226-item full screening requirements.
Centered on the client’s three mandatory procurement criteria: Australian TGA + USP compliance, 100% wild Qinba Dioscorea zingiberensis raw materials, compatibility with dual softgel and tablet production lines and stable annual supply of 21 tons, HiSiaddi eliminated Shanghe Bio (excessively high unit pricing and elevated minimum order thresholds), Jiayuan Bio (cultivated yam adulteration and insufficient compliance) and Zhejiang Natural Bio (unstable raw material supply and substandard pesticide residue control) after comprehensive evaluation of five brands across five dimensions: raw material sourcing, process technology, certification, pricing and mass production stability. Two mid-to-high-end core supply brands were finalized: Shaanxi Hongda Bio and Chenggu Zhenhua Bio, with three precisely matched product models selected to fit the client’s two production line requirements.
1. Hongda HD-DIO98B (200-mesh ultra-fine 98% saponin): Exclusive raw material for softgels. Powder processed via low-temperature nitrogen closed milling with repose angle of 33°±2° and outstanding flowability, perfectly compatible with the client’s automatic softgel filling equipment to eliminate bridging and excessive filling weight deviation. Annual procurement volume: 12.3 tons as the client’s primary mass production grade.
2. Hongda HD-DIO98A (100-mesh national standard 98% raw powder): General primary raw material for tablets. Manufactured from wild raw materials with low impurity levels, minimizing oxidative discoloration when compounded with the client’s vitamin C and mineral auxiliary materials, meeting Australia’s mandatory 24-month tablet shelf-life stability standard. Annual procurement volume: 5.2 tons.
3. Zhenhua ZH-98PH pharmacopoeia-grade 98% powder: Backup supplementary raw material for tablets. Large-scale mass production with abundant spot reserves serving as an alternative supply when Hongda production capacity is constrained, priced slightly lower than Hongda to balance overall procurement costs. Annual reserved procurement volume: 3.5 tons.
HiSiaddi coordinated both manufacturers to send 3 parallel sample batches for each model separately per Australian TGA specifications, unified for full USP and EC396 testing at SGS Australia laboratories, while compiling full qualification documents, raw material traceability ledgers and origin harvesting certificates for both manufacturers alongside bilingual English COA test reports to assist the client with pre-review of Australian importer filings.
All three rounds of samples passed full physical, pesticide residue, heavy metal and solvent residue testing at Australian laboratories, with zero process malfunctions during 8 consecutive days of small-batch mass production trials at the client’s GMP workshop. Softgel filling weight errors stabilized within ±1.9%, and tablets showed no browning or precipitation after 90 days of ambient storage, fully meeting new product launch standards. The first combined shipment of 6.8 tons split across grades was vacuum aluminum foil nitrogen-sealed and shipped from Shanghai Port to Sydney, passing one-time pre-review under Australian TGA customs regulations with zero inspection and smooth warehouse entry. Post raw material deployment, the client’s two new menopausal products successfully completed Australian pharmaceutical regulatory filing and rolled out across national premium pharmacy and organic supermarket channels, with terminal sales exceeding enterprise pre-launch forecasts by 27% in the first half-year of launch.
Based on successful brand selection delivery outcomes, Australian BioBalance signed a yearly locked-price procurement framework of 21 tons with HiSiaddi, split into 10 monthly production batches covering the three finalized products. In the following year, the client expanded its high-end hospital external skincare line requiring 95% grade diosgenin, again entrusting HiSiaddi with brand screening and sample coordination, prioritizing the two established core suppliers. Endorsed by cooperation with this mid-to-high-end Australian brand, Hongda and Zhenhua optimized export graded product lines, subsequently securing saponin orders from three equivalent high-end dietary brands in New Zealand and South Africa to steadily open stable high-end natural extract supply chains across Oceania.
This full-service delivery clearly reveals widespread supply-demand information gaps across China’s diosgenin industry: even with benign competition without malicious competitor defamation, leading domestic plant extract manufacturers prioritize promoting their own product lines under sales performance KPIs, deliberately avoiding objective disclosure of peer brand product strengths, applicable scenarios and weaknesses, resulting in one-sided information for overseas high-end clients conducting independent sourcing. Meanwhile, high-end European, American and Australian dietary pharmaceutical brands deeply master end-formulation R&D and local pharmaceutical regulatory and production standards yet lack research channels for China’s raw material origin resources, varying manufacturer process gaps and segmented applicable fields of each product model. Independent contact with multiple manufacturers easily leads to fragmented samples, chaotic indicators and misaligned brand selection, triggering sample waste, delayed new product launches and substantial economic losses.
Leveraging over a decade of industry databases and on-site research resources in plant extract foreign trade, HiSiaddi breaks marketing barriers of individual manufacturers as a neutral third party to conduct horizontal benchmarking of full-dimensional parameters across five leading domestic brands. Brand and product model selection is precisely aligned with three core client demands: end-formulation recipes, production line equipment and target market access regulations, abandoning pure low-price-oriented selection logic. Full risk mitigation for cross-border trade and production stemming from blind brand selection is delivered from multiple dimensions including raw material sourcing compliance, process compatibility, mass production stability and long-term supply security. Simultaneously, scientific neutral brand selection helps compliant domestic manufacturers with premium raw material resources escape low-price homogeneous competition, securing stable access to global high-end dietary raw material supply chains via standardized pharmaceutical-grade products to achieve mutual win-win outcomes for Chinese and foreign supply and demand sides.
Contact HiSiaddi customer service for additional brand and model comparative analysis support.
+86-13120989737 
info@hisiaddi.com 
English
